Thornburg Investment Management Inc. Has $4.70 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Thornburg Investment Management Inc. reduced its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 10.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 36,271 shares of the biotechnology company’s stock after selling 4,074 shares during the quarter. Thornburg Investment Management Inc.’s holdings in Sarepta Therapeutics were worth $4,696,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Fifth Third Bancorp boosted its stake in shares of Sarepta Therapeutics by 1,215.8% during the 4th quarter. Fifth Third Bancorp now owns 1,000 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 924 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Sarepta Therapeutics by 351.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,824 shares of the biotechnology company’s stock valued at $1,044,000 after purchasing an additional 8,427 shares during the last quarter. International Assets Investment Management LLC grew its stake in Sarepta Therapeutics by 9,382.5% in the fourth quarter. International Assets Investment Management LLC now owns 11,379 shares of the biotechnology company’s stock valued at $1,097,000 after purchasing an additional 11,259 shares in the last quarter. Tobam increased its position in Sarepta Therapeutics by 4.8% in the 4th quarter. Tobam now owns 156,046 shares of the biotechnology company’s stock worth $15,048,000 after purchasing an additional 7,105 shares during the last quarter. Finally, Sapient Capital LLC purchased a new stake in shares of Sarepta Therapeutics during the 4th quarter worth about $978,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ SRPT traded down $1.64 during mid-day trading on Wednesday, hitting $146.00. The company had a trading volume of 827,266 shares, compared to its average volume of 1,386,483. Sarepta Therapeutics, Inc. has a 12 month low of $55.25 and a 12 month high of $173.25. The firm has a market cap of $13.80 billion, a P/E ratio of 1,327.27 and a beta of 0.89. The business’s 50-day simple moving average is $137.19 and its 200-day simple moving average is $129.42. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, beating the consensus estimate of ($0.11) by $0.84. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The firm had revenue of $413.50 million during the quarter, compared to analysts’ expectations of $375.52 million. During the same quarter in the prior year, the firm posted ($1.44) EPS. The company’s revenue for the quarter was up 63.1% on a year-over-year basis. As a group, analysts predict that Sarepta Therapeutics, Inc. will post 3.76 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Dallan Murray sold 3,635 shares of the stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total value of $508,900.00. Following the completion of the transaction, the insider now owns 18,125 shares in the company, valued at approximately $2,537,500. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, insider Dallan Murray sold 3,635 shares of the company’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total value of $508,900.00. Following the sale, the insider now owns 18,125 shares of the company’s stock, valued at $2,537,500. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Ryan Edward Brown sold 38,957 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the transaction, the executive vice president now owns 17,129 shares of the company’s stock, valued at approximately $2,768,217.69. The disclosure for this sale can be found here. Insiders sold a total of 50,451 shares of company stock valued at $8,086,386 over the last ninety days. 7.70% of the stock is owned by company insiders.

Analyst Ratings Changes

SRPT has been the topic of a number of research reports. Royal Bank of Canada increased their price objective on Sarepta Therapeutics from $142.00 to $182.00 and gave the stock a “sector perform” rating in a report on Friday, June 21st. BMO Capital Markets raised their price target on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a report on Monday, June 24th. Citigroup cut shares of Sarepta Therapeutics from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $172.00 to $176.00 in a report on Wednesday, June 26th. Barclays raised their target price on Sarepta Therapeutics from $185.00 to $226.00 and gave the company an “overweight” rating in a report on Friday, June 21st. Finally, Bank of America upped their price target on Sarepta Therapeutics from $166.00 to $213.00 and gave the stock a “buy” rating in a research note on Friday, June 21st. Five research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $187.72.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.